Liu Emily, Nisenblat Vicki, Farquhar Cindy, Fraser Ian, Bossuyt Patrick M M, Johnson Neil, Hull M Louise
Fertility PLUS, Auckland District Health Board, Greenlane Clinical Centre, Private Bag 92189, Auckland, New Zealand.
Cochrane Database Syst Rev. 2015 Dec 23;2015(12):CD012019. doi: 10.1002/14651858.CD012019.
About 10% of reproductive-aged women suffer from endometriosis which is a costly chronic disease that causes pelvic pain and subfertility. Laparoscopy is the 'gold standard' diagnostic test for endometriosis, but it is expensive and carries surgical risks. Currently, there are no simple non-invasive or minimally-invasive tests available in clinical practice that accurately diagnoses endometriosis.
The searches were not restricted to particular study design, language or publication dates. We searched the following databases to 20 April - 31 July 2015: CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, Web of Science, LILACS, OAIster, TRIP and ClinicalTrials.gov (trial register). MEDION, DARE, and PubMed were also searched to identify reviews and guidelines as reference sources of potentially relevant studies. Recently published papers not yet indexed in the major databases were also sought. The search strategy incorporated words in the title, abstract, text words across the record and the medical subject headings (MeSH) and was modified for each database.
Published peer-reviewed, randomised controlled or cross-sectional studies of any size were considered, which included prospectively collected samples from any population of reproductive-aged women suspected of having one or more of the following target conditions: ovarian, peritoneal or deep infiltrating endometriosis (DIE). We included studies comparing the diagnostic test accuracy of one or more urinary biomarkers with surgical visualisation of endometriotic lesions.
Two authors independently collected and performed a quality assessment of the data from each study. For each diagnostic test, the data were classified as positive or negative for the surgical detection of endometriosis and sensitivity and specificity estimates were calculated. If two or more tests were evaluated in the same cohort, each was considered as a separate data set. The bivariate model was used to obtain pooled estimates of sensitivity and specificity whenever sufficient data sets were available. The predetermined criteria for a clinically useful urine test to replace diagnostic surgery was one with a sensitivity of 94% and a specificity of 79% to detect endometriosis. The criteria for triage tests were set at sensitivity of equal or greater than 95% and specificity of equal or greater than 50%, which in case of negative result rules out the diagnosis (SnOUT test) or sensitivity of equal or greater than 50% with specificity of equal or greater than 95%, which in case of positive result rules the diagnosis in (SpIN test).
We included eight studies involving 646 participants, most of which were of poor methodological quality. The urinary biomarkers were evaluated either in a specific phase of menstrual cycle or irrespective of the cycle phase. Five studies evaluated the diagnostic performance of four urinary biomarkers for endometriosis, including three biomarkers distinguishing women with and without endometriosis (enolase 1 (NNE); vitamin D binding protein (VDBP); and urinary peptide profiling); and one biomarker (cytokeratin 19 (CK 19)) showing no significant difference between the two groups. All of these biomarkers were assessed in small individual studies and could not be statistically evaluated in a meaningful way. None of the biomarkers met the criteria for a replacement test or a triage test. Three studies evaluated three biomarkers that did not differentiate women with endometriosis from disease-free controls.
AUTHORS' CONCLUSIONS: There was insufficient evidence to recommend any urinary biomarker for use as a replacement or triage test in clinical practice for the diagnosis of endometriosis. Several urinary biomarkers may have diagnostic potential, but require further evaluation before being introduced into routine clinical practice. Laparoscopy remains the gold standard for the diagnosis of endometriosis, and diagnosis of endometriosis using urinary biomarkers should only be undertaken in a research setting.
约10%的育龄妇女患有子宫内膜异位症,这是一种代价高昂的慢性疾病,会导致盆腔疼痛和生育力低下。腹腔镜检查是子宫内膜异位症的“金标准”诊断测试,但费用高昂且有手术风险。目前,临床实践中尚无简单的非侵入性或微创测试可准确诊断子宫内膜异位症。
检索不限于特定的研究设计、语言或出版日期。我们检索了以下数据库至2015年4月20日 - 7月31日:Cochrane系统评价数据库、医学索引数据库、荷兰医学文摘数据库、护理学与健康领域数据库、心理学文摘数据库、科学引文索引数据库、拉丁美洲及加勒比地区健康科学数据库、开放获取学位论文数据库、循证医学数据库和临床试验注册库(试验注册)。还检索了医学文摘数据库、卫生保健数据摘要库和PubMed以识别综述和指南作为潜在相关研究的参考来源。还查找了尚未在主要数据库中索引的最近发表的论文。检索策略纳入了标题、摘要、记录中的文本词以及医学主题词(MeSH)中的词,并针对每个数据库进行了修改。
考虑已发表的同行评审的任何规模的随机对照或横断面研究,其中包括前瞻性收集的来自任何怀疑患有以下一种或多种目标疾病的育龄妇女群体的样本:卵巢、腹膜或深部浸润性子宫内膜异位症(DIE)。我们纳入了比较一种或多种尿生物标志物与子宫内膜异位症病变手术可视化的诊断测试准确性的研究。
两位作者独立收集并对每项研究的数据进行质量评估。对于每项诊断测试,将数据分类为手术检测子宫内膜异位症的阳性或阴性,并计算敏感性和特异性估计值。如果在同一队列中评估了两种或更多测试,则每种测试都被视为一个单独的数据集。只要有足够的数据集,就使用双变量模型获得敏感性和特异性的汇总估计值。用于替代诊断性手术的临床有用尿液测试的预定标准是检测子宫内膜异位症的敏感性为94%,特异性为79%。分诊测试的标准设定为敏感性等于或大于95%且特异性等于或大于50%(阴性结果排除诊断(SnOUT测试))或敏感性等于或大于50%且特异性等于或大于95%(阳性结果确诊诊断(SpIN测试))。
我们纳入了八项研究,涉及646名参与者,其中大多数研究方法质量较差。尿生物标志物在月经周期的特定阶段或不考虑周期阶段进行评估。五项研究评估了四种尿生物标志物对子宫内膜异位症的诊断性能,其中包括三种区分有无子宫内膜异位症的女性的生物标志物(烯醇化酶1(NNE);维生素D结合蛋白(VDBP);以及尿肽谱);还有一种生物标志物(细胞角蛋白19(CK 19))在两组之间无显著差异。所有这些生物标志物均在小型个体研究中进行评估,无法以有意义的方式进行统计学评估。没有一种生物标志物符合替代测试或分诊测试的标准。三项研究评估了三种无法区分患有子宫内膜异位症的女性与无病对照的生物标志物。
没有足够的证据推荐任何尿生物标志物在临床实践中用作子宫内膜异位症诊断的替代或分诊测试。几种尿生物标志物可能具有诊断潜力,但在引入常规临床实践之前需要进一步评估。腹腔镜检查仍然是子宫内膜异位症诊断的金标准,使用尿生物标志物诊断子宫内膜异位症仅应在研究环境中进行。